Another Soliris biosimilar approved by FDA in 2024? | Binary | | | 7 months ago | |
Number of new biosimilars for rare blood disorders approved in 2024 | Categorical | | | 7 months ago | |
Impact of Bkemv on AstraZeneca's stock price by end of 2024 | Categorical | | | 7 months ago | |
Bkemv achieves sales target in its first year? | Binary | | | 7 months ago | |
Will severe CRS & Icans side effects from Imdelltra be reported by end of 2024? | Binary | | | 7 months ago | |
Will Imdelltra receive FDA approval for other cancer types by May 2025? | Binary | | | 7 months ago | |
Market performance of Imdelltra compared to other new cancer drugs by end of 2024 | Categorical | | | 7 months ago | |
Global approval status of Imdelltra by end of 2024 | Categorical | | | 7 months ago | |
Will Imdelltra become a blockbuster seller by May 2024? | Binary | | | 7 months ago | |
Imdelltra Sales Reach $500M by Year End? | Binary | | | 7 months ago | |
Global Approval Reach of Imdelltra by End of 2024 | Categorical | | | 7 months ago | |
Competing Drug for Imdelltra by Mid-2025? | Binary | | | 7 months ago | |
Full FDA Approval for Imdelltra by May 2025? | Binary | | | 7 months ago | |
Next major partnership for CytomX post-CX-904 success by 2024? | Categorical | | | 8 months ago | |
CytomX stock surges 30% post next CX-904 update? | Binary | | | 8 months ago | |
Fast-track FDA designation for CX-904 by end of 2024? | Binary | | | 8 months ago | |
CX-904 trials expansion to additional cancers by mid-2025? | Binary | | | 8 months ago | |
CytomX stock performance vs. biotech industry by end 2024 | Categorical | | | 8 months ago | |
Will Amgen announce a Phase 3 trial for MariTide by June 30, 2025? | Binary | | | 27 days ago | |
Will Regeneron file another legal challenge against Amgen by end of 2024? | Binary | | | 2 months ago | |
Will AbbVie file a lawsuit against UnitedHealth over Humira removal by end of 2024? | Binary | | | 3 months ago | |
Will another pharmaceutical company announce an AI-generated drug by end of 2024? | Binary | | | 5 months ago | |
Will Insilico Medicine's AI-generated drug receive FDA approval by end of 2024? | Binary | | | 5 months ago | |
Market share outcomes for PNH and aHUS treatments by end of 2024 | Categorical | | | 7 months ago | |
AstraZeneca launches a new product for PNH and aHUS in 2024? | Binary | | | 7 months ago | |
Impact of Imdelltra on Amgen's total revenue by end of 2024 | Categorical | | | 7 months ago | |
Market Share of Imdelltra by End of 2024 | Categorical | | | 7 months ago | |
Impact of Imdelltra on Patient Survival Rates by End of 2025 | Categorical | | | 7 months ago | |
Results of further CX-904 trials in pancreatic cancer by end of 2024 | Categorical | | | 8 months ago | |
Amgen stock price increase by 10% post-ASH24 by January 8, 2025? | Binary | | | 15 days ago | |
Major pharmaceutical partnership with Amgen for BLINCYTO® by mid-2025? | Binary | | | 15 days ago | |
FDA approval for expanded use of BLINCYTO® in pediatric B-cell ALL by end of 2025? | Binary | | | 15 days ago | |
Will Amgen's MariTide show >25% weight loss in Phase 3 trials by end of 2025? | Binary | | | 27 days ago | |
Which company will lead market share in obesity drugs by end of 2025? | Categorical | | | 27 days ago | |
Will Amgen's stock price recover to pre-announcement levels by March 31, 2025? | Binary | | | 27 days ago | |
Will Amgen's MariTide receive FDA approval for obesity treatment by end of 2025? | Binary | | | 27 days ago | |
Will Amgen's stock price increase by 10% or more by January 31, 2025? | Binary | | | 2 months ago | |
Will AstraZeneca's stock price increase by 10% or more by January 31, 2025? | Binary | | | 2 months ago | |
Outcome of Regeneron's appeal against Amgen ruling by end of 2025? | Categorical | | | 2 months ago | |
Will Amgen's Eylea biosimilar capture over 10% market share by end of 2025? | Binary | | | 2 months ago | |
Will UnitedHealth stock price increase by the end of Q1 2024? | Binary | | | 3 months ago | |
What will be the peak stock price of Viridian Therapeutics in Q4 2024? | Categorical | | | 3 months ago | |
Which company will bring the first AI-generated drug to market by end of 2024? | Categorical | | | 5 months ago | |
Which company will have the first AI-generated drug to receive FDA approval by end of 2024? | Categorical | | | 5 months ago | |
First region to approve BLINCYTO® for pediatric B-cell ALL post-ASH24 by end of 2025? | Categorical | | | 15 days ago | |
BLINCYTO® sales growth in the first half of 2025? | Categorical | | | 15 days ago | |
First major medical journal to feature AALL1731 trial results by March 2025? | Categorical | | | 15 days ago | |
How will Amgen's MariTide revenue compare to forecasts for FY 2025? | Categorical | | | 27 days ago | |
What level of new safety concerns will arise for MariTide by end of 2025? | Categorical | | | 27 days ago | |
How will MariTide impact Amgen's revenue in fiscal year 2025? | Categorical | | | 27 days ago | |
How will Amgen's stock price respond to MariTide Phase 2 results by end of 2024? | Categorical | | | 27 days ago | |
What will be the next step in MariTide's development by end of 2025? | Categorical | | | 27 days ago | |
Tezspire's market approval status by end of 2025 | Categorical | | | 2 months ago | |
Tezspire's impact on Amgen's revenue growth for fiscal year 2025 | Categorical | | | 2 months ago | |
Will Tezspire receive FDA approval for CRSwNP by end of 2025? | Binary | | | 2 months ago | |
Which company will emerge as the next major competitor to Tezspire by end of 2025? | Categorical | | | 2 months ago | |
Will Amgen's Eylea biosimilar receive FDA approval for additional indication by end of 2025? | Binary | | | 2 months ago | |
Which biosimilar achieves highest US sales by end of 2025? | Categorical | | | 2 months ago | |
Which company will lead eye care biosimilar market share by end of 2025? | Categorical | | | 2 months ago | |
Which biosimilar will have the highest market share by end of 2024? | Categorical | | | 3 months ago | |
Will OptumRx biosimilars capture more than 10% market share by end of 2024? | Binary | | | 3 months ago | |
What will be the market share distribution among Humira, Amjevita, and Wezlana by end of 2024? | Categorical | | | 3 months ago | |
What will be the percentage decline in AbbVie's market share for Humira by end of 2024? | Categorical | | | 3 months ago | |
What percentage of TED patients will achieve complete resolution of diplopia with VRDN-001 by the end of 2025? | Categorical | | | 3 months ago | |
What will be the primary outcome of the BLA submission for VRDN-001? | Categorical | | | 3 months ago | |
Will Viridian Therapeutics' stock price increase by more than 50% by the end of 2024? | Binary | | | 3 months ago | |
Will VRDN-001 receive FDA approval by the end of 2026? | Binary | | | 3 months ago | |
Will Viridian Therapeutics submit a BLA for VRDN-001 in 2025? | Binary | | | 3 months ago | |
Will Insilico Medicine's AI-generated drug enter Phase III clinical trials by end of 2024? | Binary | | | 5 months ago | |
Which disease will the first AI-generated drug be approved for by end of 2024? | Categorical | | | 5 months ago | |
